Press Release

PhRMA and EFPIA Applaud Push for EU-US Trade Agreement

PhRMA February 13, 2013

Washington, D.C. and Brussels (February 12, 2013) —The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) welcome today’s announcement of a new trade agreement that will strengthen economic ties between Europe and the United States.

“We believe that a high standard, comprehensive agreement will serve patients and the jobs that depend on our industry very well.  Europe and America lead the world in developing new medicines.  This Agreement can serve to develop the rules needed to speed medicines to patients.  We look forward to working with the negotiators to fulfill the promise of what will be the largest negotiated trade agreement,” said John J Castellani, President and CEO of PhRMA.”

Richard Bergstrom, Director General of EFPIA, highlighted that “This comprehensive undertaking between the EU and US is a key opportunity to deepen the already strong economic relationship. It should seek to enhance pharmaceutical research and innovation to address the needs of patients whilst fostering economic growth throughout the world.” 

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.

EFPIA represents the pharmaceutical industry operating in Europe. Through its direct membership of 31 national associations and 35 leading pharmaceutical companies, EFPIA provides the voice of 2,000 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

EFPIA members are committed to delivering innovative medicines to address unmet needs of patients and reducing the burden of chronic diseases for Europe’s ageing population. EFPIA believes in close cooperation with its stakeholders to help create sustainable healthcare systems and to develop prompt responses to health threats in Europe.